Products
TransPlus Virus Transduction Enhancer
Have questions? Contact us
TransPlus™ Virus Transduction Enhancer is a mixture of polymers optimized for the infection of lentivirus or retrovirus to most cells. It can increase the transduction rate up to 10 fold. TransPlus is provided as a 500x solution, sufficient for 100 transductions in a 24 well plate. It is intended for retroviral or lentiviral transduction.
| Product Name | TransPlus Virus Transduction Enhancer |
|---|---|
| Shipping Condition |
Room Temperature - 2 Day Shipping |
| Storage and Stability |
This product is stable for 3 months when stored in 4 °C or 6 months if store at -20 °C. |
| Quality Control | Each lot of TransPlus Virus Transduction Enhancer is tested for sterility and successful increase in transduction efficiency of viral particles. |
| Restricted Use |
For Research Use Only. Not for use in diagnostic or therapeutic procedures. |
- MS Vidal, LS Richardson, AK Kammala, S Kim… Endocrine-disrupting compounds and their impact on human placental function: evidence from placenta organ-on-chip studies. Lab on a Chip, 2024. Article
- V Golubovskaya and L Wu Anti-ROR1 antibody and ROR1-targeting engineered cells. US Patent 11,932,703, 2024. Article
- L Zhang, MEI Heng, Z Tangyi, X Chen… Bispecific cs1-bcma car-t cell and application thereof. US Patent App. 18 …, 2024. Article
- MS Vidal Jr, E Radnaa, N Vora, K Khanipov… Establishment and comparison of human term placenta–derived trophoblast cells. Biology of …, 2024. Article
- S Liu, H Chen, X Chen, N Luo, S Peraramelli… Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection. Frontiers in …, 2024. Article
- S Liu and H Chen and X Chen and N Luo and S Peraramelli and ... Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection. Frontiers in …, 2024. Article
- L Wu, V Golubovskaya Epcam antibody and Epcam-CAR-T cells. US Patent 12,227,589, 2025. Article
- V Golubovskaya, L Wu Anti-ROR1 antibody and ROR1-targeting engineered cells. US Patent 11,932,703, 2024. Article
- L Wu, V Golubovskaya Bcma-car-t cells. US Patent 12,059,436, 2024. Article
- L Wu, V Golubovskaya Humanized bcma antibody and bcma-car-t cells. US Patent 12,173,077, 2024. Article
- L Wu and V Golubovskaya Humanized bcma antibody and bcma-car-t cells. US Patent App. 18/326,826, 2023. Article
- L Wu and V Golubovskaya Pd-l1-specific antibody and anti-pd-l1-car-t cells. US Patent App. 18/002,340, 2023. Article
- L Zhang and MEI Heng and Z Tangyi and X Chen and ... Bispecific cs1-bcma car-t cell and application thereof. US Patent App. 18 …, 2024. Article
- L Wu, V Golubovskaya CAR-T cells with humanized CD19 ScFv. US Patent 12,103,970, 2024. Article
- L Wu and V Golubovskaya Chimeric antigen receptors comprising a human transferrin epitope sequence. US Patent 11,725,053, 2023. Article
- A Patakas, T London, E Cosimo Gamma delta CAR-T cells comprising Fc gamma intracellular signaling domains. US Patent 11,890,302, 2024. Article
- A Patakas and T London and E Cosimo Gamma delta CAR-T cells comprising Fc gamma intracellular signaling domains. US Patent 11,890,302, 2024. Article
- DDA Goncharov, RCV Lintao, R Urrabaz-Garza… Determining Sex-Specific Gene Expression Differences in Human Chorion Trophoblast Cells. International journal of …, 2025. Article
Have Questions?
If you don't see the product you're looking for, please don't hesitate to CONTACT US. Our dedicated team of scientists will provide you our best solutions for your desired results.